Lundbeckfond Ventures, the Denmark-based Lundbeck Foundation’s life sciences investment entity, has co-led a $17m Series A round into River Vision Development Corp, a developer of a treatment for Graves’ Orbitopathy. Lundbeckfond Ventures was joined by SR One, a corporate venturing unit of UK-based healthcare company GlaxoSmithKline. There was also involvement from Narrow River Management.
River Vision was founded by Narrow River Management for the sole purpose of developing RV001. The Company is managed under contract with Narrow River, which founds and provides leadership expertise for special purpose drug development companies.
Dave Madden, chief executive of River Vision, said: “We are delighted to be working with SR One and Lundbeckfonden on this exciting project, they bring a wealth of experience and relationships that should be invaluable to River Vision as we bring RV001 forward through development.”